Urolithin A vs. Doing Nothing: Is It Worth Starting?

Reviewed by SOMA HEALTH's Medical Research Team

Most comparisons pit one supplement against another. The more honest comparison, for a lot of people, is urolithin A versus doing nothing at all — leaving your routine exactly as it is and hoping the years take care of themselves. This guide frames that choice plainly: what the human evidence actually supports, where the research is still early, and how to weigh the quiet cost of waiting.

The comparison nobody frames honestly

When people research urolithin A, they usually imagine the decision as ‘this ingredient or that ingredient.’ In practice, the vast majority of adults are not choosing between two supplements. They are choosing between starting something with a plausible mechanism and a growing body of human data, or continuing to do nothing — the default state most of us drift in. Doing nothing feels safe because it requires no decision. But biology does not pause while you deliberate.

Mitochondria are the tiny structures inside your cells that turn food and oxygen into usable energy. As we age, the ordinary housekeeping process that clears out worn, underperforming mitochondria — a form of cellular recycling called mitophagy — tends to slow down. Damaged mitochondria accumulate. This is one of the better-characterised features of biological aging, and it is quietly under way whether or not you think about it. ‘Doing nothing’ is not a neutral position; it is a choice to let that drift continue unaddressed. You can read more about the underlying biology in our overview of mitochondrial health and our explainer on what mitophagy is.

What urolithin A actually is

Urolithin A is not a vitamin or a stimulant. It is a gut postbiotic — a compound your body produces when certain gut bacteria break down ellagitannins, the polyphenols found in pomegranates, walnuts, and some berries. Here is the catch: not everyone’s microbiome carries the bacteria needed to make meaningful amounts. Studies suggest a substantial share of people convert little or none, no matter how much pomegranate they eat. That is the core reason direct supplementation exists — it delivers the finished compound rather than relying on a conversion step your gut may not perform. For the full primer, see our urolithin A guide and the list of foods high in urolithin A precursors.

Mechanistically, urolithin A supports mitophagy: the recycling of worn-out mitochondria so cells can maintain a healthier, more efficient population of them. That is a structure-and-function idea, not a disease claim. It is also the thread that connects most of the research below.

The proven human evidence

The strongest reason to take urolithin A seriously — rather than dismissing it as another hopeful powder — is that it has been tested in people, not just petri dishes.

Safety came first (Andreux 2019)

The first-in-human trial, published in Nature Metabolism in 2019, established that urolithin A was safe and well tolerated at doses up to 1,000 mg per day. Just as importantly, it produced a measurable mitochondrial gene-expression signature in participants — early evidence that the compound was doing something biologically relevant, not merely passing through.

Muscle endurance in older adults (2022)

A randomised trial in older adults, published in JAMA Network Open in 2022, ran roughly four months and reported improvements in muscle endurance measures. This is human data in exactly the population most concerned about age-related decline.

Strength and performance in midlife (Singh 2022)

A four-month trial in middle-aged adults, published in Cell Reports Medicine, tested both 500 mg and 1,000 mg daily arms and reported benefits for muscle strength and exercise performance. The dose-ranging design is part of why 500–1,000 mg per day is the studied window. Our page on urolithin A for muscle goes deeper here.

Newer human signals

More recent human work has widened the picture. A 2025 randomised trial in Nature Aging (about 28 days) reported support for immune-cell mitochondrial health in midlife adults — relevant to the low-grade inflammation sometimes called inflammaging. A 2024 eight-week randomised trial in resistance-trained men (published in the Journal of the International Society of Sports Nutrition) and a 2025 trial in distance runners have extended testing into active and athletic populations. None of these are the last word, but together they represent an unusually deep human record for an ingredient of this kind.

Where the evidence is still early

Honesty cuts both ways. A great deal of the excitement around urolithin A traces back to preclinical research — work in cells and animals, not humans. In 2016, a landmark study in Nature Medicine (Ryu and colleagues) showed urolithin A induced mitophagy, extended lifespan in the worm C. elegans, and improved muscle measures in rodents. A 2022 study in Aging Cell explored joint and cartilage outcomes in osteoarthritis models. These are genuinely interesting, but they are preclinical: they suggest directions, they do not prove human outcomes.

Popular claims about skin, gut, brain, and heart benefits mostly sit in this early or preclinical stage — research is exploring them, and it would be dishonest to present them as settled. A 2024 systematic review in Ageing Research Reviews put it fairly: when it comes to targeting aging with urolithin A in humans, the evidence is still emerging. Starting urolithin A is a reasonable, mechanism-led bet on your mitochondrial health — not a guarantee, and not a treatment for any medical condition. If you are weighing a health concern, that is a conversation for your doctor, not a supplement label.

The real cost of waiting

So what does ‘doing nothing’ actually cost? Not a dramatic, overnight loss — that is precisely why it is easy to ignore. The decline in mitophagy and mitochondrial quality is gradual and mostly invisible until it shows up as everyday fatigue or slower recovery. The human trials above ran for weeks to months, which points to something important: urolithin A is not a stimulant that works in an hour. It is a daily-consistency compound. Every month spent deciding is a month not accumulating whatever benefit the consistent-use data describes. Our page on how long urolithin A takes to work explains the realistic timeline.

None of this argues for panic or hype. It argues for a clear-eyed decision. If the mechanism is plausible, the human safety data is solid, and the downside of a well-made, third-party-tested product is low, then ‘wait and see’ is itself a position with consequences.

How to decide, practically

If you choose to start, keep it simple. The studied dose range is 500–1,000 mg per day, with 1,000 mg at the top of what has been tested. Consistency matters more than timing — take it daily rather than chasing a perfect moment. Give it a fair trial measured in months, not days, and pair it with the basics that also support mitochondrial function: regular movement, sleep, and whole foods. For specifics, see how to take urolithin A and how to choose the best urolithin A gummies. As a comparison guide, this page is published by SOMA HEALTH, which sells a urolithin A product — so read it as an informed but commercially interested view, and cross-check the science for yourself.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.